Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric M Ruderman

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Current Pharmaceutical Design|February 22, 2005
Current and future pharmaceutical therapy for rheumatoid arthritisEric M Ruderman
Rheumatology (Oxford, England)|December 11, 2012
Overview of safety of non-biologic and biologic DMARDsEric M Ruderman
Journal of the American Academy of Dermatology|August 2, 2003
Evaluation and management of psoriatic arthritis: the role of biologic therapyEric M Ruderman
Bulletin of the Hospital for Joint Disease (2013)|October 25, 2013
Treating to target in rheumatoid arthritis - challenges and opportunitiesEric M Ruderman
Bulletin of the Hospital for Joint Disease (2013)|November 14, 2013
The role of concomitant methotrexate in biologic therapy for rheumatoid arthritisEric M Ruderman
The American Journal of Managed Care|May 7, 2002
Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient careEric M Ruderman
Nature Reviews. Rheumatology|April 25, 2015
Rheumatoid arthritis: IL-6 inhibition in RA--déjà vu all over again?Eric M Ruderman
The Journal of Rheumatology|June 3, 2015
Of Mice and Men: Defining the Role of Interleukin 17 in Rheumatoid ArthritisEric M Ruderman
Rheumatology (Oxford, England)|October 2, 2012
Defining the value of structural inhibition. Is low-dose etanercept inferior to the standard dose?Eric M Ruderman
Rheumatology (Oxford, England)|February 23, 2010
Do we really need five TNF antagonists?Eric M Ruderman
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Current Pharmaceutical Design|February 22, 2005
Current and future pharmaceutical therapy for rheumatoid arthritisEric M Ruderman
Rheumatology (Oxford, England)|December 11, 2012
Overview of safety of non-biologic and biologic DMARDsEric M Ruderman
Journal of the American Academy of Dermatology|August 2, 2003
Evaluation and management of psoriatic arthritis: the role of biologic therapyEric M Ruderman
Bulletin of the Hospital for Joint Disease (2013)|October 25, 2013
Treating to target in rheumatoid arthritis - challenges and opportunitiesEric M Ruderman
Bulletin of the Hospital for Joint Disease (2013)|November 14, 2013
The role of concomitant methotrexate in biologic therapy for rheumatoid arthritisEric M Ruderman
The American Journal of Managed Care|May 7, 2002
Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient careEric M Ruderman
Nature Reviews. Rheumatology|April 25, 2015
Rheumatoid arthritis: IL-6 inhibition in RA--déjà vu all over again?Eric M Ruderman
The Journal of Rheumatology|June 3, 2015
Of Mice and Men: Defining the Role of Interleukin 17 in Rheumatoid ArthritisEric M Ruderman
Rheumatology (Oxford, England)|October 2, 2012
Defining the value of structural inhibition. Is low-dose etanercept inferior to the standard dose?Eric M Ruderman
Rheumatology (Oxford, England)|February 23, 2010
Do we really need five TNF antagonists?Eric M Ruderman
Pageof 7